Medical Prognosis Institute A-S Aktie [WKN DE: A2AH3F / ISIN: DK0060732477]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Medical Prognosis Institute A-S

04.11.20		Allarity Therapeutics Hires New Chief Financial Officer (GlobeNewswire)
26.10.20		Allarity Therapeutics Gains Allowance from U.S. Patent and Trademark Office for New DRP® Biomarker Patents (GlobeNewswire)
23.10.20		Allarity Therapeutics Provides Update on Dovitinib Program (GlobeNewswire)
09.10.20		Allarity Therapeutics will trade under new short name ALLR starting on 12 October 2020 (GlobeNewswire)
07.10.20		Press Release Allarity Therapeutics Shareholders Approve Company Name Change and Board Appointments (GlobeNewswire)
06.10.20		Press Release Oncology Venture calls third investment tranche under its share subscription agreement with Global Corporate Finance (GlobeNewswire)
06.10.20		Press Release Oncology Venture A/S Issues 1,619,912 Shares in Exchange for Previously Annulled Warrants (GlobeNewswire)
21.09.20		Notice to Convene an Extraordinary General Meeting (GlobeNewswire)
21.09.20		Press Release Oncology Venture Plans Name Change to Allarity Therapeutics and Board Restructuring to Align with Current Company Strategy (GlobeNewswire)
28.08.20		Press Release Oncology Venture Publishes Interim Report for the Period January – June 2020 (GlobeNewswire)
26.08.20		Press Release Oncology Venture’s Novel PARP Inhibitor Stenoparib (formerly 2X-121) Shows Anti-Viral Activity Against Coronavirus in Pre-Clinical Studies (GlobeNewswire)
21.08.20		Press Release Oncology Venture will offer new shares in exchange for previously annulled warrants as part of clean-up of remaining obligations incurred prior to former management departure (GlobeNewswire)
21.08.20		Press Release Oncology Venture calls second investment tranche under its share subscription agreement and issues 5,980,020 shares to Global Corporate Finance (GlobeNewswire)
14.08.20		Press Release Oncology Venture issues 1,893,939 shares to Negma Group LTD and Park Partners GP and thereby all outstanding convertible loan notes are converted (GlobeNewswire)
14.07.20		Press Release Oncology Venture is issuing 2,255,639 shares under its existing convertible loan note agreement with Negma Group LTD and Park Partners GP (GlobeNewswire)
13.07.20		Press release Oncology Venture acquires full ownership of its PARP inhibitor (2X-121) program (GlobeNewswire)
30.06.20		Press Release Oncology Venture is issuing 1,574,803 shares under its existing convertible loan note agreement with Negma Group LTD and Park Partners GP (GlobeNewswire)
29.06.20		Press release Oncology Venture signs agreement to out-license two pipeline assets as part of prioritized portfolio strategy (GlobeNewswire)
18.06.20		Press release Oncology Venture is issuing 5,177,584 shares under its share subscription agreement with Global Corporate Finance (GlobeNewswire)
11.06.20		Press Release Oncology Venture terminates agreement with liquidity provider (GlobeNewswire)
10.06.20		Press Release Oncology Venture is issuing 2,255,639 shares under its convertible note agreement with Negma Group LTD and Park Partners GB (GlobeNewswire)
09.06.20		Press Release Oncology Venture calls first investment tranche of SEK 10 million under its share subscription agreement with Global Corporate Finance (GlobeNewswire)
09.06.20		Press Release Oncology Venture is issuing 751,879 shares under its convertible note agreement with Negma Group LTD and Park Partners GB (GlobeNewswire)
08.06.20		Press release Oncology Venture acquires full control of Dovitinib program (GlobeNewswire)
29.05.20		Company Announcement Oncology Venture Publishes Q1 2020 Report for the Period January – March 2020 (GlobeNewswire)
07.05.20		Press release Oncology Venture issues 1,952,475 new shares in connection with debt conversions (GlobeNewswire)
06.05.20		Press release Oncology Venture secures a US $5 million (50 million SEK) equity investment from a new US based investor (GlobeNewswire)
22.04.20		Minutes from Annual General Meeting 2020 (GlobeNewswire)
22.04.20		Press release Oncology Venture to test activity of its PARP inhibitor, 2X-121, as a potential therapy for Coronavirus (GlobeNewswire)
17.04.20		Press Release Oncology Venture is issuing 925,925 shares under its convertible note agreement with Negma Group LTD and Park Partners GB (GlobeNewswire)
07.04.20		Notice to convene Annual General Meeting 2020 (GlobeNewswire)
03.04.20		Press Release Oncology Venture draws down the first tranche under its Convertible note agreement with Negma Group LTD and Park Partners GB (GlobeNewswire)
31.03.20		Press Release Oncology Venture publishes the Annual Report for 2019 (GlobeNewswire)
31.03.20		Press release Oncology Venture establishes a convertible note program of 100 million SEK (GlobeNewswire)
20.03.20		Press release Oncology Venture receives feedback from U.S. FDA on potential approval pathway for Dovitinib. (GlobeNewswire)
26.02.20		Press release Oncology Venture to present on its DRP® technology at upcoming Google Cloud NEXT Conference. (GlobeNewswire)
24.02.20		Press release Oncology Venture & Alpha Blue Ocean mutually terminates agreement with EHGO as part of final financing (GlobeNewswire)
31.01.20		Press release Oncology Venture – First day of trading in TO2 warrants (GlobeNewswire)
13.01.20		Press release Oncology Venture to present a poster at upcoming PARP & DDR Inhibitor Summit on clinical development of 2X-121 (GlobeNewswire)
10.01.20		Press release Oncology Venture issues 287,500 new shares in connection with a debt conversion (GlobeNewswire)
12.12.19		Press release Swedish financier Mats Gabrielsson becomes major shareholder in Oncology Venture (GlobeNewswire)
05.12.19		Press release Oncology Venture rights issue fully subscribed (GlobeNewswire)
29.11.19		Company Announcement Oncology Venture publishes Interim Report for the period January – September 2019 (GlobeNewswire)
13.11.19		Oncology Venture advancing towards next milestone in its clinical development of IXEMPRA®. (GlobeNewswire)
12.11.19		Oncology Venture can inform that the last trading day of the Subscription Rights is now 19 November 2019, following the extension of subscription period until the 21 November of the current rights iss (GlobeNewswire)
12.11.19		Oncology Venture extends the subscription period of the current rights issue (GlobeNewswire)
12.11.19		Oncology Venture advancing towards next milestone in its clinical development of 2X-121. (GlobeNewswire)
12.11.19		Oncology Venture reaches new development milestone with Dovitinib. (GlobeNewswire)
12.11.19		Oncology Venture is streamlining its communications by publishing press releases in English only going forward. (GlobeNewswire)
21.10.19		The Board of Oncology Venture resolves to conduct a rights issue of new shares, and publishes prospectus regarding the rights issue (GlobeNewswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Flugzeugabsturz nahe Vilnius: DHL-Auftragnehmer in schweren Unfall verwickelt - DHL-Aktie etwas schwächer

Italiens UniCredit will Banco BPM schlucken - Scheitert jetzt die Commerzbank-Übernahme? - Aktien unter Druck

Pierer Mobility-Aktie zieht zweistellig an: Pierer Industrie AG hat Restrukturierungsverfahren eingeleitet

Bitcoin im Fokus: MicroStrategy sorgt für Spannung mit potenziellen Käufen

Erstes Alarmsignal seit 2008: Droht dem Aktienmarkt eine Krise?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	27.11.2024 17:34
Kaufwert:	EUR
	Hinzufügen Speichern